Feasibility study of moderate dose of cisplatin-based chemotherapy with short hydration for advanced lung cancer
Not Applicable
- Conditions
- advanced lung cancer
- Registration Number
- JPRN-UMIN000004493
- Lead Sponsor
- Okayama Lung Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
pts with active co-morbidities including severe conditions of heart diseases, gastric ulcers, infections, uncontrollable diabetes, psychlogicai diseases, hypertension, active interstitial and hearing loss. pts with active other cancers detected within the past 3 years. pts with massive pleural and cardiac effusion and ascites that need to be immediately treated pts with symptomatic brain metastases pts who will receive CDDP of less than 60 mg/m²/day
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method feasibility of cisplatin-based chemotherapy with short hydration
- Secondary Outcome Measures
Name Time Method